vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
DYNAVAX TECHNOLOGIES CORP的季度营收约是REGIS CORP的1.7倍（$94.9M vs $57.1M），DYNAVAX TECHNOLOGIES CORP净利率更高（28.4% vs 0.8%，领先27.6%），REGIS CORP同比增速更快（22.3% vs 17.7%），DYNAVAX TECHNOLOGIES CORP自由现金流更多（$32.6M vs $891.0K），过去两年DYNAVAX TECHNOLOGIES CORP的营收复合增速更高（30.6% vs 7.8%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
DVAX vs RGS — 直观对比
营收规模更大
DVAX
是对方的1.7倍
$57.1M
营收增速更快
RGS
高出4.6%
17.7%
净利率更高
DVAX
高出27.6%
0.8%
自由现金流更多
DVAX
多$31.7M
$891.0K
两年增速更快
DVAX
近两年复合增速
7.8%
损益表 — Q3 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $57.1M |
| 净利润 | $26.9M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | 22.4% | 10.8% |
| 净利率 | 28.4% | 0.8% |
| 营收同比 | 17.7% | 22.3% |
| 净利润同比 | 53.0% | -94.0% |
| 每股收益（稀释后） | $0.21 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVAXRGS
| Q4 25 | — | $57.1M | ||
| Q3 25 | $94.9M | $59.0M | ||
| Q2 25 | $95.4M | $60.4M | ||
| Q1 25 | $68.2M | $57.0M | ||
| Q4 24 | $72.0M | $46.7M | ||
| Q3 24 | $80.6M | $46.1M | ||
| Q2 24 | $73.8M | $49.4M | ||
| Q1 24 | $50.8M | $49.2M |
净利润DVAXRGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | $26.9M | $1.4M | ||
| Q2 25 | $18.7M | $116.5M | ||
| Q1 25 | $-96.1M | $250.0K | ||
| Q4 24 | $7.0M | $7.6M | ||
| Q3 24 | $17.6M | $-853.0K | ||
| Q2 24 | $11.4M | $91.2M | ||
| Q1 24 | $-8.7M | $-2.3M |
营业利润率DVAXRGS
| Q4 25 | — | 10.8% | ||
| Q3 25 | 22.4% | 10.0% | ||
| Q2 25 | 15.1% | 12.1% | ||
| Q1 25 | -34.7% | 8.8% | ||
| Q4 24 | -2.3% | 11.8% | ||
| Q3 24 | 12.5% | 4.6% | ||
| Q2 24 | 7.0% | — | ||
| Q1 24 | -35.0% | 8.3% |
净利率DVAXRGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | 28.4% | 2.3% | ||
| Q2 25 | 19.6% | 192.9% | ||
| Q1 25 | -141.0% | 0.4% | ||
| Q4 24 | 9.8% | 16.4% | ||
| Q3 24 | 21.8% | -1.9% | ||
| Q2 24 | 15.4% | 184.7% | ||
| Q1 24 | -17.2% | -4.7% |
每股收益（稀释后）DVAXRGS
| Q4 25 | — | $0.16 | ||
| Q3 25 | $0.21 | $0.49 | ||
| Q2 25 | $0.14 | $43.67 | ||
| Q1 25 | $-0.77 | $0.08 | ||
| Q4 24 | $0.07 | $2.71 | ||
| Q3 24 | $0.12 | $-0.36 | ||
| Q2 24 | $0.08 | $38.40 | ||
| Q1 24 | $-0.07 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $534.1M | $188.7M |
| 总资产 | $946.5M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资DVAXRGS
| Q4 25 | — | $18.4M | ||
| Q3 25 | $160.2M | $16.6M | ||
| Q2 25 | $99.1M | $17.0M | ||
| Q1 25 | $51.7M | $13.3M | ||
| Q4 24 | $95.9M | $10.2M | ||
| Q3 24 | $119.3M | $6.3M | ||
| Q2 24 | $112.5M | $10.1M | ||
| Q1 24 | $132.0M | $5.9M |
总债务DVAXRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益DVAXRGS
| Q4 25 | — | $188.7M | ||
| Q3 25 | $534.1M | $187.6M | ||
| Q2 25 | $494.2M | $185.6M | ||
| Q1 25 | $530.9M | $68.6M | ||
| Q4 24 | $596.8M | $66.7M | ||
| Q3 24 | $681.4M | $56.4M | ||
| Q2 24 | $642.8M | $56.8M | ||
| Q1 24 | $618.5M | $-35.8M |
总资产DVAXRGS
| Q4 25 | — | $588.3M | ||
| Q3 25 | $946.5M | $592.1M | ||
| Q2 25 | $918.4M | $599.0M | ||
| Q1 25 | $945.9M | $511.2M | ||
| Q4 24 | $986.3M | $530.1M | ||
| Q3 24 | $1.1B | $508.9M | ||
| Q2 24 | $1.0B | $530.5M | ||
| Q1 24 | $986.6M | $543.7M |
负债/权益比DVAXRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $891.0K |
| 自由现金流率自由现金流/营收 | 34.4% | 1.6% |
| 资本支出强度资本支出/营收 | 1.3% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.26× | 3.65× |
| 过去12个月自由现金流最近4个季度 | $80.5M | $14.9M |
8季度趋势，按日历期对齐
经营现金流DVAXRGS
| Q4 25 | — | $1.7M | ||
| Q3 25 | $33.8M | $2.3M | ||
| Q2 25 | $23.4M | $6.8M | ||
| Q1 25 | $-19.6M | $6.2M | ||
| Q4 24 | $53.0M | $2.1M | ||
| Q3 24 | $19.5M | $-1.3M | ||
| Q2 24 | $10.7M | $5.1M | ||
| Q1 24 | $-16.7M | $-277.0K |
自由现金流DVAXRGS
| Q4 25 | — | $891.0K | ||
| Q3 25 | $32.6M | $1.9M | ||
| Q2 25 | $22.0M | $6.2M | ||
| Q1 25 | $-23.6M | $5.9M | ||
| Q4 24 | $49.5M | $1.7M | ||
| Q3 24 | $18.1M | $-1.4M | ||
| Q2 24 | $9.9M | $5.1M | ||
| Q1 24 | $-17.4M | $-326.0K |
自由现金流率DVAXRGS
| Q4 25 | — | 1.6% | ||
| Q3 25 | 34.4% | 3.2% | ||
| Q2 25 | 23.0% | 10.3% | ||
| Q1 25 | -34.6% | 10.3% | ||
| Q4 24 | 68.8% | 3.6% | ||
| Q3 24 | 22.5% | -3.0% | ||
| Q2 24 | 13.5% | 10.3% | ||
| Q1 24 | -34.3% | -0.7% |
资本支出强度DVAXRGS
| Q4 25 | — | 1.4% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 1.5% | 0.9% | ||
| Q1 25 | 5.8% | 0.6% | ||
| Q4 24 | 4.8% | 0.9% | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.5% | 0.1% |
现金转化率DVAXRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | 1.26× | 1.68× | ||
| Q2 25 | 1.25× | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | 7.52× | 0.28× | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
